



Current Agreements

Dealdoc

Collaboration and option agreement for cell therapy for cardiovascular application

Capricor Therapeutics
Janssen Biotech

Jan 06 2014

Collaboration and option agreement for cell therapy for cardiovascular application

Companies:	Capricor Therapeutics Janssen Biotech
Announcement date:	Jan 06 2014
Deal value, US\$m:	337.5 : sum of upfront and option fee

- [Details](#)
- [Financials](#)
- [Termsheet](#)
- [Press Release](#)
- [Filing Data](#)
- [Contract](#)

Details

Announcement date:	Jan 06 2014
Industry sectors:	Bigpharma Biotech Pharmaceutical
Compound name:	CAP-1002
Exclusivity:	Exclusive
Asset type:	Compound
Therapy areas:	Cardiovascular » Myocardial Infarction
Technology types:	Regenerative medicine » Cell therapy Bigpharma outlicensing Collaborative R&D
Deal components:	Licensing Option
Stages of development:	Phase II

Financials

Deal value, US\$m:	337.5 : sum of upfront and option fee
Upfront, US\$m:	12.5 : upfront payment
Milestones, US\$m:	325 : option exercising fee for licensing
Royalty rates, %:	n/d : royalty on commercial sales of CAP-1002

Termsheet

Capricor Therapeutics has executed a collaboration agreement and exclusive license option with Janssen Biotech.

Capricor and Janssen agreed to collaborate on the development of Capricor's cell therapy program for cardiovascular applications, including its lead product, CAP-1002.

CAP-1002 is an allogeneic cardiosphere-derived cell therapeutic under evaluation in patients who have suffered a large myocardial infarction.

Capricor and Janssen will collaborate on elements of cell manufacturing development.

Capricor will contribute to the costs of the manufacturing collaboration, and will receive an upfront payment of \$12.5 million from Janssen.

Janssen has the right to enter into an exclusive license agreement for CAP-1002 at any time until sixty days following delivery by Capricor of the six-month follow-up results from Phase II of Capricor's ALLSTAR clinical trial for CAP-1002.

If Janssen exercises its option rights, Capricor will be eligible to receive up to \$325 million in additional payments.

In addition, a royalty would be paid on commercial sales of CAP-1002.

Press Release

Little Biotech, Capricor Therapeutics, Inc. Inks Heart Pact Worth \$337.5 Million With Johnson & Johnson (JNJ)'s Janssen Biotech Inc. (JNJ)

Capricor Therapeutics and Janssen Biotech, Inc. Enter Into Collaboration Agreement and Exclusive License Option

LOS ANGELES, Jan. 6, 2014 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (OTCBB:CAPR) today announced that it has executed a collaboration agreement and exclusive license option with Janssen Biotech, Inc. (Janssen). Under the terms of the agreement, Capricor and Janssen agreed to collaborate on the development of Capricor's cell therapy program for cardiovascular applications, including its lead product, CAP-1002. CAP-1002 is an allogeneic cardiosphere-derived cell (CDC) therapeutic under evaluation in patients who have suffered a large myocardial infarction. Pursuant to the agreement, Capricor and Janssen will collaborate on elements of cell manufacturing development. Capricor will contribute to the costs of the manufacturing collaboration, and will receive an upfront payment of \$12.5 million from Janssen.

Under the terms of the agreement, Janssen has the right to enter into an exclusive license agreement for CAP-1002 at any time until sixty days following delivery by Capricor of the six-month follow-up results from Phase II of Capricor's ALLSTAR clinical trial for CAP-1002. If Janssen exercises its option rights, Capricor will be eligible to receive up to \$325 million in additional payments. In addition, a royalty would be paid on commercial sales of CAP-1002.

"This collaboration with Janssen, one of the world's largest and most respected healthcare companies with a strong presence in cardiovascular and metabolism, is a tremendous milestone for Capricor Therapeutics and an important validation of our lead product, CAP-1002, and the underlying science. We are proud to be working with Janssen to support the continued development of CAP-1002 and for the additional non-dilutive capital to further our research and development that will add to our pipeline," said Capricor CEO, Dr. Linda Marbán.

About Capricor Therapeutics

Capricor Therapeutics, Inc. (CAPR), a publicly traded biotechnology company, is focused on the development of novel therapeutics to prevent and treat heart disease. The Company has two leading product candidates: CAP-1002 and Cenderitide. The Company was formed through the November 2013 merger between Capricor, Inc., a privately held company whose mission is to improve the treatment of heart disease by commercializing cardiac stem cell therapies for patients, and Nile Therapeutics, Inc., a clinical-stage biopharmaceutical company developing innovative products for the treatment of cardiovascular diseases. Capricor Therapeutics' stock began trading under the symbol "CAPR" December 20, 2013. For additional information visit www.capricor.com.

About CAP-1002

CAP-1002, Capricor's lead product candidate, is a proprietary allogeneic adult stem cell therapy for the treatment of heart disease. The product is derived from donor heart tissue. The cells are expanded in the laboratory using a specialized process and then introduced directly into a patient's heart via infusion into a coronary artery using standard cardiac catheterization techniques.

CAP-1002 is currently not an approved product and is strictly for investigational purposes.

Filing Data

Not available.

Contract

Not available.